Toll Free: 1-888-928-9744
Published: Dec, 2015 | Pages:
32 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Inventiva SAS - Product Pipeline Review - 2015 Summary Global Markets Direct's, 'Inventiva SAS - Product Pipeline Review - 2015', provides an overview of the Inventiva SAS's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Inventiva SAS's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Inventiva SAS including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Inventiva SAS's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Inventiva SAS's pipeline products Reasons to Buy - Evaluate Inventiva SAS's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Inventiva SAS in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Inventiva SAS's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Inventiva SAS and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Inventiva SAS - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Inventiva SAS and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Inventiva SAS Snapshot 5 Inventiva SAS Overview 5 Key Information 5 Key Facts 5 Inventiva SAS - Research and Development Overview 6 Key Therapeutic Areas 6 Inventiva SAS - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Inventiva SAS - Pipeline Products Glance 11 Inventiva SAS - Clinical Stage Pipeline Products 11 Phase II Products/Combination Treatment Modalities 11 Phase I Products/Combination Treatment Modalities 12 Inventiva SAS - Early Stage Pipeline Products 13 Preclinical Products/Combination Treatment Modalities 13 Discovery Products/Combination Treatment Modalities 14 Inventiva SAS - Drug Profiles 15 IVA-337 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 odiparcil 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 Small Molecule for Autoimmune Disease 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 Small Molecule for Immuno-Oncology 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 Small Molecule to Inhibit G9A for Ovarian Cancer 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 Small Molecule to Inhibit NSD2 for Multiple Myeloma 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 Small Molecule to Inhibit YAP/TEAD Interaction for Oncology 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 Small Molecules to Inhibit EZH2 for Non-Hodgkin Lymphoma 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Inventiva SAS - Pipeline Analysis 23 Inventiva SAS - Pipeline Products by Target 23 Inventiva SAS - Pipeline Products by Route of Administration 24 Inventiva SAS - Pipeline Products by Molecule Type 25 Inventiva SAS - Pipeline Products by Mechanism of Action 26 Inventiva SAS - Recent Pipeline Updates 27 Inventiva SAS - Dormant Projects 28 Inventiva SAS - Discontinued Pipeline Products 29 Discontinued Pipeline Product Profiles 29 IVA-337 29 Inventiva SAS - Locations And Subsidiaries 30 Head Office 30 Appendix 31 Methodology 31 Coverage 31 Secondary Research 31 Primary Research 31 Expert Panel Validation 31 Contact Us 31 Disclaimer 32
List of Tables
Inventiva SAS, Key Information 5 Inventiva SAS, Key Facts 5 Inventiva SAS - Pipeline by Indication, 2015 8 Inventiva SAS - Pipeline by Stage of Development, 2015 9 Inventiva SAS - Monotherapy Products in Pipeline, 2015 10 Inventiva SAS - Phase II, 2015 11 Inventiva SAS - Phase I, 2015 12 Inventiva SAS - Preclinical, 2015 13 Inventiva SAS - Discovery, 2015 14 Inventiva SAS - Pipeline by Target, 2015 23 Inventiva SAS - Pipeline by Route of Administration, 2015 24 Inventiva SAS - Pipeline by Molecule Type, 2015 25 Inventiva SAS - Pipeline Products by Mechanism of Action, 2015 26 Inventiva SAS - Recent Pipeline Updates, 2015 27 Inventiva SAS - Dormant Developmental Projects,2015 28 Inventiva SAS - Discontinued Pipeline Products, 2015 29
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.